APVO vs. AMPE, ATHX, SXTC, CALA, ADTX, BLPH, EVFM, SBFM, EVLO, and SPRC
Should you be buying Aptevo Therapeutics stock or one of its competitors? The main competitors of Aptevo Therapeutics include Ampio Pharmaceuticals (AMPE), Athersys (ATHX), China SXT Pharmaceuticals (SXTC), Calithera Biosciences (CALA), Aditxt (ADTX), Bellerophon Therapeutics (BLPH), Evofem Biosciences (EVFM), Sunshine Biopharma (SBFM), Evelo Biosciences (EVLO), and SciSparc (SPRC). These companies are all part of the "pharmaceutical preparations" industry.
Aptevo Therapeutics (NASDAQ:APVO) and Ampio Pharmaceuticals (NYSE:AMPE) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, community ranking, profitability, analyst recommendations, media sentiment, dividends, institutional ownership, valuation and risk.
Aptevo Therapeutics received 198 more outperform votes than Ampio Pharmaceuticals when rated by MarketBeat users. Likewise, 52.66% of users gave Aptevo Therapeutics an outperform vote while only 0.00% of users gave Ampio Pharmaceuticals an outperform vote.
Aptevo Therapeutics' return on equity of -112.27% beat Ampio Pharmaceuticals' return on equity.
Ampio Pharmaceuticals has lower revenue, but higher earnings than Aptevo Therapeutics.
Aptevo Therapeutics has a beta of 5.13, suggesting that its stock price is 413% more volatile than the S&P 500. Comparatively, Ampio Pharmaceuticals has a beta of 2.14, suggesting that its stock price is 114% more volatile than the S&P 500.
8.1% of Aptevo Therapeutics shares are owned by institutional investors. Comparatively, 5.7% of Ampio Pharmaceuticals shares are owned by institutional investors. 0.3% of Aptevo Therapeutics shares are owned by company insiders. Comparatively, 3.3% of Ampio Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
In the previous week, Aptevo Therapeutics had 1 more articles in the media than Ampio Pharmaceuticals. MarketBeat recorded 2 mentions for Aptevo Therapeutics and 1 mentions for Ampio Pharmaceuticals. Aptevo Therapeutics' average media sentiment score of 0.30 beat Ampio Pharmaceuticals' score of 0.00 indicating that Aptevo Therapeutics is being referred to more favorably in the media.
Summary
Aptevo Therapeutics beats Ampio Pharmaceuticals on 10 of the 12 factors compared between the two stocks.
Get Aptevo Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for APVO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding APVO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aptevo Therapeutics Competitors List
Related Companies and Tools
